
CDK8-IN-12
CAS No. 2613307-67-6
CDK8-IN-12( —— )
Catalog No. M36414 CAS No. 2613307-67-6
CDK8-IN-12 is a selective, potent and orally active inhibitor of CDK8 (Ki: 14 nM) and is an anti-cancer agent.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 111 | Get Quote |
![]() ![]() |
5MG | 163 | Get Quote |
![]() ![]() |
10MG | 242 | Get Quote |
![]() ![]() |
25MG | 403 | Get Quote |
![]() ![]() |
50MG | 586 | Get Quote |
![]() ![]() |
100MG | 803 | Get Quote |
![]() ![]() |
200MG | 1098 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameCDK8-IN-12
-
NoteResearch use only, not for human use.
-
Brief DescriptionCDK8-IN-12 is a selective, potent and orally active inhibitor of CDK8 (Ki: 14 nM) and is an anti-cancer agent.
-
DescriptionCDK8-IN-12 is an orally active, potent CDK8 inhibitor with a Ki of 14 nM. CDK8-IN-12 has off-target kinase inhibition on GSK-3α, GSK-3β, PCK-θ with Kis of 13 nM, 4 nM, 109 nM, respectively. CDK8-IN-12 shows potent anti-proliferative effects selectively on MV4-11 cell. CDK8-IN-12 is an anti-cancer agent.
-
In VitroWestern Blot Analysis Cell Line:MV4-11 cells Concentration:0.36, 0.72 μM Incubation Time:2 hours Result:Significantly reduced the phosphorylation of serine 727 on STAT1 at concentrations of their respective 1× GI50 values, but barely affected the level of total STAT1.
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetGSK-3
-
RecptorGSK-3 | CDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2613307-67-6
-
Formula Weight381.86
-
Molecular FormulaC21H20ClN3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C2(CCN(CC2)C=3C(=CN=CC3Cl)C4=CC=5C(O4)=CC=CC5)CCN1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mingfeng Yu, et al. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation. Eur J Med Chem. 2021 Mar 15;214:113248.?
molnova catalog



related products
-
Tideglusib
Tideglusib is an irreversible, non ATP-competitive GSK-3β inhibitor with IC50 of 60 nM in a cell-free assay.
-
BRD5648
BRD5648 is an inactive (R)-enantiomer of BRD0705.
-
GSK3-IN-2
GSK3-IN-2 is a potent GSK3 inhibitor for the treatment of diabetes and neurodegenerative diseases.